Founded with a mission to revolutionize protein production, MNPHARM leverages advanced genetic engineering and controlled indoor agriculture to produce high-quality, affordable recombinant proteins. The company focuses on the regenerative medicine market, aiming to lower the costs of essential proteins for therapeutic development. Their proprietary plant-based protein expression methods ensure rapid and efficient production, catering primarily to the research community.
MNPHARM's notable achievements include the successful production of VEGF-165 and PLAP/AALP proteins, which are critical in regenerative therapies. The company has attracted significant interest from investors focused on biotech innovations. By eliminating animal components from their production process, MNPHARM not only enhances safety but also sets new standards in the industry. Their impact is marked by making cutting-edge regenerative treatments more accessible and affordable.
